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Background
Hypomanic symptoms may be a useful predictor of mood
disorder among young people at high risk for bipolar disorder.
Aims
To determine whether hypomanic symptoms differentiate
offspring of parents with bipolar disorder (high risk) and
offspring of well parents (control) and predict the development
of mood episodes.
Method
High-risk and control offspring were prospectively assessed
using semi-structured clinical interviews annually and
completed the Hypomania Checklist-32 Revised (HCL-32).
Clinically significant sub-threshold hypomanic symptoms
(CSHS) were coded.
Results
HCL-32 total and active or elated scores were higher in control
compared with high-risk offspring, whereas 14% of high-risk
and 0% of control offspring had CSHS. High-risk offspring with
CSHS had a fivefold increased risk of developing recurrent
major depression (P=0.0002). The median onset of CSHS in
high-risk offspring was 16.4 (6–31) years and was before the
onset of major mood episodes.
Conclusions
CSHS are precursors to major mood episodes in high-risk
offspring and could identify individuals at ultra-high risk for
developing bipolar disorder.
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Bipolar disorder is a severe psychiatric disorder with peak onset in
late adolescence and early adulthood.1 Bipolar disorder is ranked
among the top 10 medical illnesses associated with the most
disability worldwide.2 Difficulty in accurate diagnosis early in the
course of illness contributes to this substantial illness burden and, in
turn, worsened prognosis because of delayed and potentially
harmful treatment.3 Given the high heritability, family history is
the most robust risk factor for predicting bipolar disorder and
identifies a high-risk population,4 informative for development of
clinical monitoring and early intervention strategies, and research
into antecedent and prodromal features. Among individuals at
confirmed genetic risk, bipolar disorder typically debuts as a
depressive episode, preceding the first manic episode by an average
of 4 years.5,6 However, there is substantial variability in clinical
course between individuals. International research efforts have
focused on identifying antecedent clinical precursors to bipolar
disorder to refine risk prediction, improve early detection and
prevent progression of the impairing disease.7 However, at present,
it is challenging to predict among those at confirmed familial risk
who will transition to full-blown bipolar disorder and related major
mood disorders.8
Evidence from the Flourish Canadian high-risk offspring
cohort study demonstrated that non-specific psychiatric disorders
precede the onset of bipolar disorder in a substantial proportion
of high-risk offspring, including sleep, anxiety and minor mood
disorders.6,9 Similar findings have been reported in other indepen-
dent international high-risk cohort studies.10–12 Antecedent symp-
tom-level psychopathology may also be evident and informative in
the prediction of bipolar disorder and related major mood disorder
onset. Other high-risk and clinical studies have reported associa-
tions between sub-threshold hypomanic symptoms (not meeting
full DSM-IV criteria) and subsequent diagnosable episodes of
(hypo)mania in offspring of a parent with bipolar disorder.13–17
This finding requires replication based on prospective observations
and further investigation. For example, it remains unclear if sub-
threshold hypomanic symptoms are more common in offspring
at confirmed familial risk compared with those not at familial risk
and if they have the same clinical importance in these different
populations. Although hypomanic symptoms are commonly reported
in general and clinical populations, not all individuals reporting these
symptoms develop bipolar disorder.18–20 Some studies using clinical
and community populations report that sub-threshold hypomanic
symptoms are precursors to full onset bipolar disorder in adults and
predict conversion from unipolar major depressive disorder (MDD)
to bipolar disorder,21,22 whereas other studies report no progression
to bipolar disorder in children and adolescents,20 or progression only
when in conjunction with other clinical predictors,22 or when
particularly persistent over adolescence.23
Taken together, sub-threshold hypomanic symptoms measured
by several informants or clinical assessment may be useful in
the prediction of bipolar disorder onset or conversion to bipolar
disorder among individuals with other risk factors such as a
confirmed familial risk. This study sought to determine whether
self-reported hypomanic symptoms measured by the Hypomania
Checklist-32 Revised (HCL-32) or clinically significant sub-
threshold hypomanic symptoms (CSHS) diagnosed by a clinician
are associated with the onset of bipolar disorder. In particular, our
study objectives were to determine (1) if HCL-32 scores (self-rated)
are correlated with clinician determined CSHS; (2) if hypomanic
symptoms (self-rated and clinician determined) differentiate high-
risk offspring of parents with bipolar disorder (high risk) from
offspring of well parents (controls) and within those at high risk,
differentiate subgroups based on the lithium response of the parent;
and (3) within high risk, determine the predictive utility and timing
of sub-threshold hypomanic symptoms in the onset of major mood
disorders.
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Method
Recruitment
Participants were high-risk and control offspring enrolled in the
Flourish Canadian high-risk offspring cohort study. Recruitment
and procedures for this dynamic cohort study are described in
detail elsewhere.6,24 Briefly, high-risk offspring were recruited,
starting in 1996, from large multi-generational families identified
through an adult patient with confirmed bipolar disorder I.25
Probands and affected first-degree relatives with bipolar disorder
I, bipolar disorder II or in a subset recurrent MDD who had
children were approached for recruitment into the high-risk study
given the evidence that recurrent mood disorders in relatives of
patients with bipolar disorder I reflects the bipolar disorder
diathesis.26 Lithium response of probands was determined based
on a validated scale and previously described clinical criteria.27 The
other parent was confirmed to have no major DSM-IV psychiatric
disorders at baseline to control for assortative mating. Control
offspring were recruited from schools in Ottawa from parents con‐
firmed to have no major DSM-IV psychiatric disorders at baseline.
All diagnoses in both parents were confirmed by Schedule for
Affective Disorders – Present and Lifetime Version (SADS-PL),28
semi-structured interviews by psychiatrists specialising in mood
disorders, and were verified by blind consensus review with at least
two additional psychiatrists.
Procedure
Consenting high-risk and control offspring were clinically assessed
annually by a child and adolescent psychiatrist specialising in mood
disorders using the Kiddie-SADS-PL29 semi-structured interview.
As part of the semi-structured interview, sub-threshold hypomanic
symptoms were systematically documented. The operationalised
criteria to confirm CSHS included (1) participant endorsed a
minimum of three DSM-IV hypomanic symptoms, but did not
meet full DSM-IV criteria for hypomania or bipolar disorder not
otherwise specified episode based on duration or severity; (2)
symptoms represented a clear change from normal functioning,
endorsed by self and others that knew the person well; and (3)
no evidence of major impairment. All diagnoses (including CSHS)
in high-risk and control offspring were confirmed by a blind
consensus review with at least two additional psychiatrists. As part
of the high-risk study, during each annual research assessment
remitted or well offspring completed the HCL-32.30 Parents
completed the Hollingshead socio-economic status (SES) scale,31
which is a validatedmeasure of SES comprising a composite score of
both working spouses highest achieved education and occupation.
This research was approved by the local Independent Research
Ethics Board in Ottawa, Ontario.
HCL-32 first revision
The HCL-3230 is a 32-item self-report questionnaire originally
designed to assess hypomanic symptoms among patients with
MDD. A score of 14 or more is considered a clinically significant
level of bipolar symptoms and cut-offs of >12 and >3 have been
established for active or elated and irritable or risk-taking subscales,
respectively.30 The HCL-32 has been well validated in clinical
populations,30,32 with coefficients alpha ranging between 0.8
and 0.9.32 For this analysis, owing to the age cut-off of the HCL-
32, only high-risk and control offspring aged 15 years and over were
included.
Data analysis
This study involved repeated measures within individuals and
interdependency among individuals because of more than one
sibling in a family. Linear mixed-effect models (LMEMs) and
shared frailty models were used to account for these design aspects.
In particular, analyses pertaining to repeated HCL-32 continuous
scores involved LMEMs. All LMEMs were adjusted for baseline
age, HCL-32 assessment time and gender. A normally distri‐
buted random intercept for each individual (or each family, if
multiple observations per family) was added to each LMEM
which takes into account the interdependence among observations.
The random intercept and residuals of fit must follow an
approximately normal distribution, or the validity of the results
may be compromised. Generalised linear mixed models with
the logit link function were used wherever fundamental model
assumptions for LMEM were not satisfied and thus the outcome
had to be dichotomised (i.e. when examining HCL-32 scores using
established cut-offs).
Shared frailty models, adjusted for gender were used to
determine the association between CSHS and time to MDD and
bipolar disorder onset. All cases in which amajor depressive episode
or activated episode (hypomanic, manic or mixed) occurred before
the onset of CSHS or HCL-32 completion date were omitted from
the analysis to ensure temporality. For individuals without any
major depressive or activated episode, the observation period was
censored at their age at last assessment; also age from date of birth
was used as the beginning of observation period as this study uses
an open, dynamic design, where participants enter the study at
different times and ages. Hazard ratios and their corresponding 95%
confidence intervals (CI) are reported and reflect, for example, the
increase in hazard of first-onset episode of major depression or
activated episode given prior CSHS compared to the absence of
these symptoms. Owing to the age cut-off (≥15 years) and our
dynamic study design, participants completing the HCL-32 were a
subset of the entire sample; therefore, all models pertaining to the
HCL-32 are of a different and smaller sample size compared with
models pertaining to CSHS.
Results
Descriptive characteristics
A total of 283 high-risk and 87 control offspring were prospectively
assessed as part of the Canadian Flourish high-risk offspring
cohort study, and of these, 156 high-risk and 45 control offspring
completed the HCL-32 at least once. In the entire sample, the mean
age at last interview was 23.3 years [standard deviation (s.d.)=8.3]
in high-risk and 20.5 (s.d.=4.0) in control offspring. Approximately
60.0% of high-risk and control offspring were female, and control
offspring had slightly higher proportions in upper class SES
Hollingshead groups compared with high-risk offspring (Table 1).
Mean follow-up time in years in high-risk offspring was 6.9
(s.d.=5.4, median 7.0, range 0.0–19.8) and in control offspring was
5.5 (s.d.=3.3, median 5.0, range 0.0–10.8). The pattern of differ-
ences in demographic variables remained similar among the subset
of offspring completing the HCL-32 (156 high-risk and 45 control
offspring) (data not shown). At the time of this analysis, high-risk
and control offspring completed up to four repeated HCL-32
measures during annual clinical visits. The mean age in years when
completing the baseline HCL-32 in high-risk offspring was 24.8
(s.d.=6.2) and in control offspring was 21.0 (s.d.=2.4).
At the time of the last observation for this analysis, 21.0%
(n=60) of high-risk offspring had a hierarchical lifetime diagnosis
of MDD, 8.5% (n=24) bipolar disorder II and 5.6% (n=16) bipolar
disorder I. Twenty-one per cent (n=59) of the high-risk offspring
had a lifetime history of substance use disorder (SUD), 29% (n=82)
anxiety disorder and 19% (n=55) sleep disorder at last observation
with 63, 57 and 47% of these cases being comorbid with a mood
disorder lifetime diagnosis, respectively. At last observation, the
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control offspring had low rates of major mood disorders as
described in detail elsewhere.6 Only two control offspring had a
diagnosis of MDD (4.3%), whereas the remainder of the control
offspring were unaffected for any lifetime major mood disorder
(Table 1). Clinically significant sub-threshold hypomanic symptoms
(CSHS) were present in 14% (40) of high-risk offspring compared
with 0% of control offspring, and most of these cases (n=32, 80%)
were among high-risk offspring with a diagnosed major mood
disorder by last observation. The median age at onset of CSHS in
high-risk offspring was 16.4 years (range=6.0–30.7). Among those
high-risk offspring with CSHS (n=40) and who developed a major
mood disorder, the median ages at onset for these hierarchical
lifetime diagnoses were 16.8 years for MDD, 18.4 years for bipolar
disorder I and 21.0 years for bipolar disorder II (Fig. 1).
HCL-32 scores in high-risk and control offspring
Adjusted HCL-32 total scores were significantly higher in control
compared with high-risk offspring (P=0.0165). Active or elated and
irritable or risk-taking subscale scores were analysed using estab-
lished cut points (>12 and >3) as the residuals were not normally
distributed. Control offspring met criteria for active or elation
significantly more than high-risk offspring (P=0.0176), whereas
irritability or risk taking was not significantly different between the
groups (P=0.9087) (Table 2). We included a variable indicating the
presence of diagnosable (hypo)mania before completing the base-
line HCL-32 measure in high-risk offspring into each model with
HCL-32 total scores, active or elated and irritable or risk-taking
subscale cut-offs as the outcome, and after the inclusion of this
variable, the group differences in HCL-32 total scores and the active
Table 1 Demographic and clinical characteristics of the sample
High-risk offspring Control offspring P
N 283 87
Age at last interview, mean (s.d.) 23.31 (8.31) 20.25 (4.02) 0.001a
Gender, n (%) Female 169 (59.72) 51 (58.62) 0.8554b
Male 114 (40.28) 36 (41.38)
SES, n (%) 1 1 (0.36) 0 (0.00) 0.0346c
2 7 (2.52) 3 (3.45)
3 30 (10.79) 2 (2.30)
4 101 (36.33) 27 (31.03)
5 139 (50.00) 55 (63.22)
Lithium response, n (%) Responder 118 (41.84) – –
Non-responder 164 (58.16) –
Major depression, n (%) 60 (21.20) 2 (4.30) <0.0001c
Mean age onset major depression (s.d.) 17.81 (4.64) 20.22 (4.23) 0.9125a
Bipolar disorder I n (%) 16 (5.65) 0 (0) –
Mean age onset bipolar disorder I (s.d.) 19.93 (5.19) – –
Bipolar disorder II n (%) 24 (8.48) 0 (0) –
Mean age onset bipolar disorder II (s.d.) 20.40 (5.32) – –
CSHS, n (%) 40 (14.13) 0 (0.00) –
Mean age onset CSHS (s.d.) 17.89 (5.22) – –
CSHS, clinical significant sub-threshold hypomanic symptoms; s.d., standard deviation; SES, socio-economic status.
a. T-test.
b. Chi-square test.
c. Fisher’s exact test.
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Fig. 1 Median ages of onset of clinically signiﬁcant sub-threshold hypomanic symptoms (CSHS), major depressive disorder (MDD) and bipolar
disorder I and II in the 40 high-risk offspring with CSHS and subsequent onset of MDD, bipolar disorder I or bipolar disorder II.
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or elated subscale became non-significant (beta (b)=1.5, standard
error (s.e.)=1.3, P=0.2312) and (b=1.0, s.e.=0.8, P=0.2265), respec-
tively. Irritability or risk taking remained similar between the
groups after including prior diagnosable (hypo)mania to the mixed
model (b=0.2, s.e.=0.4, P=0.6827).
There were significant differences in the contextual questions
from the HCL-32. Namely, 100% of control offspring endorsed that
they experienced a high (as defined by the items from the prior
question in the measure) in the past 12 months compared with 77%
of high-risk offspring (P=0.0021). Other’s reactions and comments
to the offspring self-reported highs were marginally different
between high-risk and control offspring (P=0.0595), where a large
proportion of control offspring endorsed positive reactions to their
highs from other people (64% compared with 38% of high-risk
offspring). No control offspring endorsed negative reactions
compared with 4% of high-risk offspring (Table 3).
The presence of CSHS was positively and significantly asso-
ciated with HCL-32 baseline scores (b=3.7, s.e.=0.8, P=0.0000).
High-risk offspring with prior CSHS reported HCL-32 total scores
that were 3.7 units higher than those without CSHS. In high-risk
offspring, proband lithium response was not significantly associated
with repeated HCL-32 total scores (b=0.5, s.e.=1.2, P=0.6907),
active or elated (b=0.2, s.e.=0.40, P=0.5168) or irritable or risk-
taking subscale scores (b=0.1, s.e.=0.4, P=0.6993) after adjusting
for gender, time and baseline age. Proband lithium response was
also not significantly associated with CSHS in high-risk offspring
(b=−0.1, s.e.=0.5, P=0.8956).
Hypomanic symptoms and the onset of MDD, bipolar
disorder II and bipolar disorder I
Given the design of this dynamic cohort study (recruiting
offspring from ages 5 to 25 years as they became available), there
were not enough cases of diagnosable major mood disorders that
occurred after the completion of the HCL-32 measure; therefore,
the numbers were too low to prospectively estimate the associa-
tion between HCL-32 scores and subsequent onset of major mood
disorder. Mean scores in remitted or well offspring, high-risk
offspring with a lifetime diagnosis of mood disorder and control
offspring are presented in Table 4.
Although CSHS were not significantly associated with the
subsequent lifetime diagnosis of MDD (hazard ratio=1.1,
P=0.8647, 95% CI=0.4, 2.6), when separating out lifetime recurrent
MDD from lifetime single episode MDD, CSHS were significantly
associated with the development of lifetime recurrent MDD
(hazard ratio 5.1, P=0.0002, 95% CI=2.1, 12.4) (Fig. 2). Clinically
significant hypomanic symptoms were indicative of risk of the
subsequent development of bipolar disorder II, however, this was
not statistically significant (hazard ratio 2.0, P=0.2146, 95%
CI=0.7, 5.7).
Discussion
The main findings from this prospective cohort study of offspring
of parents with bipolar disorder compared with offspring of well
parents include (1) clinically determined but not self-reported
hypomanic symptoms differentiated high-risk from control off-
spring; (2) within high-risk offspring, there is evidence of con-
cordance of clinically determined and self-report measures of
hypomanic symptoms; and (3) hypomanic symptoms that are
assessed to be of clinical importance in young people at familial risk
predict onset of recurrent MDD – often heralding the onset of
bipolar disorder in this population.
Self-reported hypomanic symptoms in the control offspring
appeared to have a different meaning than in the high-risk
offspring. This was evidenced by the paradoxical finding of higher
total and active or elated HCL-32 scores in control compared with
high-risk offspring, with 100% of control offspring endorsing
experiencing such highs, despite 0% of clinically determined cases
of bipolar disorder or CSHS and a high proportion of control
offspring endorsing positive responses by other towards their
reported highs. Moreover, when accounting for a prior diagnosable
hypo(manic) episode in high-risk offspring, HCL-32 scores were
no longer different between high-risk and control offspring and
were strongly associated with prior CSHS, suggesting that self-
reported hypomanic symptoms may be more clinically meaningful
in offspring at confirmed familial high risk. Other studies have
reported similar, contradictory findings pertaining to the HCL-32
in general population and control samples, where scores are
surprisingly high (meeting the established cut-offs for possible
bipolarity)33 and sometimes higher than clinical samples of patients
with bipolar disorder I and bipolar disorder II.34
There are a few possible explanations for this finding. First, the
high-risk offspring in this sample were in clinical remission when
completing self-reported measures, and therefore, their responses
may look similar to control offspring responses. Second, given that
the majority of high-risk offspring were exposed to some form of
their parents’ mood disorder35 and 18% experienced (hypo)mania
themselves, the high-risk offspring may have a different pers‐
pective or point of comparison influencing their ranking of
hypo(manic) symptoms compared with control offspring. That is,
the two populations may be measuring different constructs (i.e.
normal mood fluctuation v. psychopathology). General population
and control samples may exhibit different baselines for ‘highs’
described in the HCL-32. Despite endorsing higher HCL-32 total
and active or elated scores, only one control offspring reported that
their highs were equal to or longer than 4 days and no control
offspring endorsed negative reactions from other people to these
highs, with most reactions reported as positive. Third, other
unaccounted for variables may influence HCL-32 scores and
reflect hypomanic-like symptoms (particularly related to the
active or elated subscale). For example, one study36 found that
intense romantic love in adolescents was associated with higher
HCL-32 scores compared with adolescents not endorsing this
experience.
These possible explanations of the paradoxical finding of
higher HCL-32 total and active or elated subscale scores in
control offspring compared with high-risk offspring do not
discredit the measure’s utility in clinical or high-risk populations,
Table 2 Differences in HCL-32 scores over time between high-risk and control offspring adjusted for gender, time and baseline age
High-risk mean (s.d.) Control mean (s.d.) betaa s.e. P
HCL-total 15.65 (6.06) 17.52 (5.53) 2.342b 0.968 0.0165
HCL-active or elated 11.29 (3.58) 12.64 (3.35) 0.915c 0.379 0.0176
HCL-irritability or risk taking 1.83 (2.16) 1.94 (1.83) 0.053c 0.465 0.9087
HCL, Hypomania Checklist; s.d., standard deviation.
a. Each row reflects a separate adjusted model.
b. Linear mixed model.
c. Generalised linear mixed model.
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but warrants discretion of its use in the general population of
young people, where high scores may not necessarily indicate
clinically significant hypomanic symptoms, but rather a differ-
ent conceptualisation of the construct of ‘high mood’. These
findings are specific to the HCL-32 within this study cohort and
cannot extend to other measures of hypomanic symptoms (e.g.
Mood Disorders Questionnaire); however, replication of these
findings using other commonly used measures in patient
populations could be insightful into their utility in non-clinical
populations.
Although the earliest DSM-IV diagnosable hypomanic episode
in this cohort so far has been at age 12.5 years, this analysis showed
that CSHS are evident in high-risk children as early as 6 years of age.
There are no reported cases of CSHS in our control sample. In high-
risk offspring, CSHS strongly increased the hazard of developing
recurrent MDD and were indicative of risk for bipolar disorder II
onset – but failed to reach significance in the latter case likely due
to low power. Interestingly, prior CSHS were only significantly
associated with recurrent MDD, but not when cases of MDD single
episode were added to the group. Moreover, CSHS manifested
before the development of major mood disorders in high-risk
offspring, just before the median age at onset of MDD and
approximately 2 and 4.5 years before the onset of meeting lifetime
diagnostic criteria for bipolar disorder I and bipolar disorder II,
respectively. Taken together, this finding lends supporting evidence
that CSHS predict the development of bipolar disorder in high-risk
offspring, as MDD is often the index mood episode of bipolar
disorder, and recurrence of mood episodes has been characterised
as the hallmark of bipolar disorder.37 These findings are in
agreement with other high-risk studies13,15 and underscore the
potential clinical utility of using CSHS to help predict among
individuals at genetic risk, who will transition to the early stages and
full onset bipolar disorder.
The following study limitations should be considered when
interpreting these findings. We did not have enough cases of major
mood disorder occurring before completion of the baseline HCL-32
measure, therefore were unable to estimate the association between
self-reported hypomanic symptoms and first onset MDD, bipolar
disorder I or bipolar disorder II. Similarly, there were not enough
cases of bipolar disorder I occurring before CSHS and the number of
cases of bipolar disorder II and MDD were low, limiting statistical
power. The models pertaining to HCL-32 scores were in a smaller
subset of the entire cohort owing to the age cut-off from themeasure
(15+). These missing data were not due to refusal to complete the
measure, or drop out, and the subset cohort was not significantly
different on key characteristics reported in Table 1 compared with
the entire cohort making the likelihood of a selection bias low.
However, some of these models had low power, impacting the
variance, potentially making estimates appear less significant. There
may have been other potential confounders not accounted for,
particularly in models pertaining to self-reported hypomanic
symptoms, such as positive life experiences, which may have
influenced the findings. In this high-risk cohort, and others, anxiety
and sleep disorders tend to onset before mood disorder and may
represent an early manifestation of the bipolar disorder illness,6
however SUDs are likely an effect modifier, where, the association
between CSHS and mood disorder may be magnified among those
with SUD. Unfortunately, we did not have enough cases of mood
disorder to test this. Future research should explore how psychiatric
comorbidity influences these associations. Some risk of retro-
spective recall bias is inevitable in naturalistic cohort studies using
an open, dynamic design, where in some cases the outcome
occurred before baseline. However, in this analysis, any instance
of the outcome occurring before the completion of the HCL-32 or
before CSHS were omitted from the analysis to ensure temporality,
therefore, using these baselines, all data used in this analysis were
prospectively captured.
These results have implications for the potential clinical utility
of identifying CSHS in high-risk offspring early in development
to help identify an ultra-high-risk population suitable for close
monitoring and early intervention. These findings also underscore
the importance of using several criteria to inform a bipolar
disorder diagnosis including a detailed family history and clinical
assessment with reports from multiple informants and cautions
against the use of reliance on self-reported symptom level data in
isolation as a predictive tool.
Table 4 HCL-32 total and subscale scores in high-risk and control offspring
Total mean (s.d.) Active or elated mean (s.d.) Irritable or risk taking mean (s.d.)
High-risk (n=156) 15.65 (6.06) 11.29 (3.58) 1.83 (2.16)
Control (n=45) 17.52 (5.53) 12.64 (3.35) 1.94 (1.83)
Within high-risk only
Unaffected (n=129) 15.51 (5.65) 11.50 (3.70) 1.57 (1.67)
MDD (n=44) 15.87 (6.09) 11.55 (3.54) 1.72 (2.08)
Bipolar disorder II (n=16) 18.96 (7.10) 11.80 (3.00) 3.56 (3.05)
Bipolar disorder I (n=12) 18.88 (6.43) 12.46 (3.0) 3.11 (3.18)
MDD, lifetime hierarchical diagnosis of major depression; s.d., standard deviation.
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Fig. 2 The hazard of recurrent major depression in high-risk
offspring with and without prior clinically signiﬁcant sub-threshold
hypomanic symptoms.
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